Pharmacoepidemiology is the applied science that bridges clinical pharmacology and epidemiology, focusing on the use and effects of medications in large, real-world populations. It evaluates the benefits, risks, and patterns of drug utilization after a medication reaches the market. Because modern clinical trials are typically limited in duration and participant diversity, this field is critical for identifying rare adverse effects, assessing long-term efficacy, and monitoring drug interactions in specialized groups (e.g., the elderly, pregnant individuals). The discipline integrates the clinical context of pharmacology with the= statistical and observational methodologies of epidemiology. Pharmacoepidemiology bridges the gap between clinical pharmacology and epidemiology. This comprehensive reference book delivers unmatched guidance on examining the use, benefits, and adverse effects of drugs in large populations. This book explores the complete landscape of postmarketing drug surveillance and real-world data application; Seamlessly integrates viewpoints and practices from academia, the pharmaceutical industry, and global regulatory bodies like the FDA and EMA; Delivers a robust "toolkit" covering complex study designs, sample sizes, automated databases, and quantitative analytical approaches; and Offers a deep dive into medical record linkages, health registries, and safety monitoring systems across North America and Europe.
Dr. Stephen Bell holds a Ph.D. in Epidemiology from Johns Hopkins Bloomberg School of Public Health and an M.D. from the University of Oxford. He is a leading expert in drug safety and public health, specializing in how medications affect large populations. With decades of experience bridging clinical medicine and biostatistics, his work focuses on identifying rare adverse effects and translating complex health data into actionable, lifesaving policies. His background and professional philosophy highlight his approach to the field: He has published over 150 peer-reviewed papers on post-market drug surveillance, vaccine safety, and risk-benefit analysis in pharmacology. Stephen believes that patient safety extends far beyond initial clinical trials. He champions the use of real-world evidence (RWE) to monitor medications in diverse, everyday populations. His engaging and accessible writing style demystifies biostatistics and epidemiology, making critical concepts understandable for students, healthcare providers, and policymakers alike. He is a frequent contributor to major medical journals and serves as an advisory board member for the International Society of Pharmacoepidemiology. Pharmacoepidemiology is his magnum opus, bringing together decades of his teaching and practical field experience into a single, comprehensive guide.
Preface 1. WHAT IS PHARMACOEPIDEMIOLOGY..............................................................1 1.1 Introduction 1.2 Pharmacoepidemiology Versus Clinical Pharmacology 1.3 Historical Background 1.4 Legislative Actions Resulting from Drug Crises 1.5 The Current Drug Approval Process 2. STUDY DESIGNS AVAILABLE FOR PHARMACOEPIDEMIOLOGIC STUDIES......21 2.1 Introduction 2.2 Overview of the Scientific Method 2.3 Epidemiologic Study Designs 2.4 Conclusion 3. SAMPLE SIZE CONSIDERATIONS FOR PHARMACOEPIDEMIOLOGIC STUDIES............................................................40 3.1 Introduction 3.2 Sample Size Calculations for Cohort Studies 3.3 Sample Size Calculations for Case–Control Studies 3.4 Sample Size Calculations for Case Series 4. CLINICAL PHARMACOLOGY RELEVANT TO PHARMACOEPIDEMIOLOGIC STUDIES............................................................53 4.1 Introduction 4.2 Clinical Pharmacology and Pharmacoepidemiology 4.3 Organ Impairment 4.4 Pharmacodynamics 4.5 Model-Informed Drug Development 4.6 Conclusion 5. WHEN SHOULD ONE PERFORM PHARMACOEPIDEMIOLOGIC STUDIES?......72 5.1 Introduction 5.2 Reasons to Perform Pharmacoepidemiologic Studies 5.3 Clinical 5.4 Safety Versus Risk 5.5 Conclusion 6. VIEWS FROM ACADEMIA, INDUSTRY, REGULATORY AGENCIES, AND THE LEGAL SYSTEM.................................................................................85 6.1 Introduction 6.2 The Drug Approval Process 6.3 Evaluation of Patients’ Use of Drugs in the Health Care System 6.4 Summary Points for the View from Academia 6.5 Epidemiology in Drug Safety Evaluation 6.6 The View from Regulatory Agencies 6.7 The View from the Legal System 7. POSTMARKETING SPONTANEOUS PHARMACOVIGILANCE REPORTING SYSTEMS.............................................126 7.1 Introduction 7.2 Description 7.3 Overview of Pharmacovigilance Reporting Systems 7.4 Strengths 7.5 Limitations 7.6 Particular Applications 8. ELECTRONIC DATABASES IN PHARMACOEPIDEMIOLOGY............................150 8.1 Introduction 8.2 Description 8.3 Strengths 8.4 Weaknesses 8.5 Particular Applications 8.6 The Future 9. ENCOUNTER DATABASES...............................................................................157 9.1 Introduction 9.2 Description 9.3 Attributes of Encounter Databases 9.4 Selected Encounter Databases 9.5 Strengths 9.6 Limitations 9.7 Particular Applications 9.8 The Future 10. ELECTRONIC HEALTH RECORD DATABASES...................................................192 10.1 Introduction 10.2 Description 10.3 Overview of Databases 10.4 Strengths 10.5 Limitations 11. PRIMARY DATA COLLECTION FOR PHARMACOEPIDEMIOLOGY..................209 11.1 Introduction 11.2 Research Questions that Require Primary Data 11.3 Methods of Primary Data Collection 11.4 Conclusions 12. TRANSPLANTATION.......................................................................................220 12.1 Introduction 12.2 Choosing Among the Available Approaches to Pharmacoepidemiologic Studies 12.3 Conclusion 13. VACC
$280.00